B. Braun Announces FDA Approval of OTC Wound Management Gel

B. Braun has announced its Prontosan Wound Management Gel with PHMB (Polyhexanide) has received 510(k) FDA for over-the-counter use.

Advertisement

 

Prontosan is used for cleaning wounds as well as moistening and lubricating absorbent wound dressings.

 

The ready-to-use gel contains PHMB and Betaine, the surfactant for the cleansing and moistening of wounds.

 

“Effective wound care management no longer needs to be limited to within healthcare facility walls,” said Mike Kelly, director of marketing, infection control products for B. Braun Medical, according to a news release. “The 510(k) clearance for OTC use of ProntosanWound Management Gel advances B. Braun’s commitment to infection prevention, helping to provide solutions that positively impact patients’ care — in a physician’s office, acute care setting or in a patient’s home.”

 

Read the B. Braun news release about Prontosan.

 

Read more about B. Braun:

 

Aesculap Implant Systems, a B. Braun Company, Launches New Patient Education Website

 

B. Braun Medical Production Facility in Switzerland Receives FDA Approval

 

B. Braun Announces Availability of Large Volume Heparin Infusion Solutions

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.